Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-07-19
2011-07-19
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S158100, C530S387300, C530S388240
Reexamination Certificate
active
07981414
ABSTRACT:
The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.
REFERENCES:
patent: 5994510 (1999-11-01), Adair
patent: 6821505 (2004-11-01), Ward
patent: 7141653 (2006-11-01), Greenfeder
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 2003/0143682 (2003-07-01), Nicolaides et al.
patent: 2003/0199679 (2003-10-01), Adair
patent: 2004/0101905 (2004-05-01), Brekke
patent: 2004/0132101 (2004-07-01), Lazar
patent: 2005/0226863 (2005-10-01), Colby
patent: 2005/0271663 (2005-12-01), Ignatovich et al.
patent: 2006/0024308 (2006-02-01), Crea
patent: 2006/0034845 (2006-02-01), Silence
patent: 2006/0038027 (2006-02-01), O'Conner
patent: 2006/0073141 (2006-04-01), Ignatovich et al.
patent: 2006/0083747 (2006-04-01), Winter
patent: 2007/0003549 (2007-01-01), Ignatovich et al.
patent: 2007/0111281 (2007-05-01), Sondermann
patent: 2007/0202105 (2007-08-01), Doyle et al.
patent: 2007/0269449 (2007-11-01), Walczak
patent: 2008/0071063 (2008-03-01), Allan
patent: 2008/0095767 (2008-04-01), Jennings et al.
patent: 2008/0139790 (2008-06-01), Jennings et al.
patent: 2008/0227958 (2008-09-01), Thompson
patent: 2008/0241166 (2008-10-01), Tomlinson et al.
patent: 2008/0255343 (2008-10-01), Jennings et al.
patent: 2008/0260738 (2008-10-01), Moore
patent: 2009/0075338 (2009-03-01), Moore
patent: 2009/0081233 (2009-03-01), Ignatovich et al.
patent: 2009/0148905 (2009-06-01), Ashman
patent: 2009/0221803 (2009-09-01), Dall'Acqua
patent: 2009/0258012 (2009-10-01), Ignatovich et al.
patent: 2009/0286962 (2009-11-01), Woolven et al.
patent: WO 88/01649 (1988-03-01), None
patent: WO-93/02108 (1993-02-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 2004/058820 (2004-07-01), None
patent: WO 2004/058821 (2004-07-01), None
patent: WO 2004/058822 (2004-07-01), None
patent: WO-2005/003345 (2005-01-01), None
patent: WO-2005/003345 (2005-01-01), None
patent: WO-2005/035572 (2005-04-01), None
patent: WO-2005/035572 (2005-04-01), None
patent: WO-2005/047325 (2005-05-01), None
patent: WO-2005/047325 (2005-05-01), None
patent: WO 2005/063816 (2005-07-01), None
patent: WO-2006/003388 (2006-01-01), None
patent: WO-2006-003388 (2006-01-01), None
patent: WO 2006003388 (2006-01-01), None
patent: WO-2006/096653 (2006-09-01), None
patent: WO-2007/070979 (2007-06-01), None
patent: WO 2009/006520 (2009-01-01), None
patent: WO 2009/134776 (2009-11-01), None
patent: WO 2009/143472 (2009-11-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor 1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Harmsen and Haard. Properties, production and applications of camelid single domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, vol. 77, pp. 13-22.
Muyldermans and Lauwereys. Unique single domain antigen binding fragments derived from naturally occurring camel heavy chain antibodies. Journal of Molecular Recognition, 1999. vol. 12, pp. 131-140.
Brekke, O.H. et al. (1995). “The Structural Requirements for Complement Activation by IgG: Does it Hinge on the Hinge?,”Immunology Today16(2):85-90.
Davies, J. et al. (1996). “Affinity Improvement of Single Antibody VH Domains: Residues in all Three Hypervariable Regions Affect Antigen Binding,”Immunotechnology2:169-179.
Foote, J. et al. (1992). “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol. 224:487-499.
Hwang, W.Y.K. et al. (2005). “Use of Human Germline Genes in a CDR Homolgy-Based Approach to Antibody Humanization,”Methods36:35-42.
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525.
Non-Final Office Action mailed Nov. 4, 2009, for U.S. Appl. No. 11/670,261, filed Feb. 1, 2007, 12 pages.
Reiter, Y. et al. (1999). “An Antibody Single-Domain Phage Display Library of a Native Heavy Chain Variable Region: Isolation of Functional Single-Domain VH Molecules with a Unique Interface,”J. Mol. Biol. 290:685-698.
Rudikoff, S. et al. (Mar. 1982). “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”Proc. Natl. Acad. Sci. USA79:1979-1983.
Saerens, D. et al. (2005, e-pub. Jul. 25, 2005). “Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies,”J. Mol. Biol. 352:597-607.
Schneider, W.P. et al. (Apr. 1988). “Genetically Engineered Immunoglobulins Reveal Structural Features Controlling Segmental Flexibility,”Proc. Natl. Acad. Sci. USA85:2509-2513.
Supplementary European Search Report mailed Jun. 18, 2009, for EP Application No. 06828046.0, nine pages.
Demarest, S.J. et al. (Sep. 2008). “Antibody Therapeutics, Antibody Engineering, and the Merits of Protein Stability,”Curr. Opin. Drug Discov. Devel. 11(5):675-687. (Abstract Only.).
Martin, A.C.R. (2008). “The Kabat Numbering Scheme,” located at <http://www.bioinf.org.uk/abs/>, last visited Mar. 9, 2008, eight pages.
Paz, K. et al. (Nov. 2005). “Human Single-Domain Neutralizing lntrabodies Directed Against Etk Kinase: A Novel Approach to Impair Cellular Transformation,”Mo. Cancer Ther. 4(11):1801-1809.
Brorson, K. et al. (1999). “Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,”The Journal of Immunology163:6694-6701.
Brummell, D.A. et al. (Feb. 1993). “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,”Biochemistry32:1180-1187 (Abstract from PubMed only.).
Burks, E.A. et al. (Jan. 1997). “In Vitro Scanning Saturation Mutagenesis of an Antibody Binding Pocket,”Proc. Natl. Acad. Sci. USA94:412-417.
Casset, F. et al. (2003). “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,”Biochemical and Biophysical Research Communications307:198-205.
Chen, Y. et al. (1999). “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen,”J. Mol. Biol. 293:865-881.
Colman, P.M. (1994). “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”Research in Immunol. 145:33-36.
De Pascalis, R. et al. (2002). “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,”The Journal of Immunology169:3076-3084.
Dufner, P. et al. (2006, e-pub. Sep. 26, 2006). “Harnessing Phage and Ribosome Display for Anti-body Optimisation,”Trends Biotechnol. 24(11):523-529.
Holm, P. et al. (2007). “Functional Mapping and Single Chin Construction of the Anti-Cytokeratin 8 Monoclonal Antibody TS1,”Mol. Immunol. 44:a1075-1084.
Jang, Y.-J. et al. (1998). “The Structural Basis for DNA Binding by an Anti-DNA Autoantibody,”Mol. Immunol. 35:1207-1217.
Kobayashi, H. et al. (1999). “Tryptophan H33 Plays an Important Role in Pyrimidine (6-4) Pyrimidone Photoproduct Bindi
Doyle Anthony G.
Jennings Philip A.
Lee Jennifer A.
Tomlinson Ian M.
Woolven Benjamin P.
Cephalon Australia Pty Ltd
Gussow Anne M.
LandOfFree
Anti-inflammatory dAb does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory dAb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory dAb will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738205